Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms.
BACKGROUND
The effect of angiotensin converting enzyme inhibitors (ACEIs) on 1.25-dihydroxyvitamin D [1.25-(OH)2D] levels has not been studied. The purpose of this study is to assess the relationship between 1.25-dihydroxyvitamin D levels and I/D angiotensin-converting enzyme polymorphism (ACE) in hypertensive patients.


METHODS
The study included 60 individuals (31 females and 29 males) with systolic and/or diastolic hypertension. The 25-hydroxyvitamin D levels were measured by HPLC and the 1.25-(OH)2 D was determined by RIA. ACE polymorphism was analyzed by Polymerase Chain Reaction (PCR) using a modification of the original method described by Rigat.


RESULTS
Treatment with ACEIs produced an increase in total calcium (p=0.003) and a decrease in the 1.25-(OH)2 D (p=0.0001). No relationship between final calcium and 1.25-(OH)2 D (r=-0.171, p=0.198) was observed. When the effects of enalapril and quinapril were analyzed separately, the results were similar. When the patients were divided according to genotype, the decrease in 1.25-(OH)2 D was observed only in patients with D allele, genotype Ins/Del (69+/-23 vs. 48+/-19, p=0.021 ) and in those of genotype Del/Del (64+/-19 vs. 17, p=0.004).


CONCLUSIONS
The ACE inhibitors in combination with the presence of the DD genotype decrease the level of 1.25-(OH)2 D. There was no difference between enalapril and quinapril treated groups.
Pérez-Castrillón
J L
JL
Departamento de Medicina Interna, Hospital Universitario Río Hortega, Facultad de Medicina de Valladolid, Valladolid, Spain. castrv@terra.es
Justo
I
I
Sanz
A
A
De Luis
D
D
Dueñas
A
A
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002117:Calcitriol / Q000097:blood*; D002118:Calcium / Q000378:metabolism; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D000077583:Quinapril; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044005:Tetrahydroisoquinolines; D004656:Enalapril; D007703:Peptidyl-Dipeptidase A; D002117:Calcitriol; D000077583:Quinapril; D002118:Calcium